The HER2-positive BC group accounts for approximately 15–25% of all BCs, and it is characterized by high tumour growth rates and aggressive clinical behaviour [53] linked also to cellular lipids deregulation [44,54,55]. This evidence concerns the gene ERBB2 and breast cancer.